{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T01:37:28Z","timestamp":1775612248142,"version":"3.50.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Bladder cancer is a prevalent and costly malignancy characterized by significant heterogeneity in presentation and clinical outcomes. This study aimed to classify the molecular subtypes of bladder cancer using immunohistochemistry (IHC) and to evaluate the prognosis, treatment responsiveness, and clinical utility of IHC-based subtype classification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed the data of 84 patients with bladder cancer who underwent radical cystectomy. Immunohistochemistry was performed using the markers CK5\/6, CK14, CK20, GATA3, and UPK2. Molecular subtypes were identified through hierarchical clustering, and statistical analyses were conducted to evaluate cancer-specific survival (CSS) and recurrence-free survival (RFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 68 patients included in the final analysis, 52 were classified as luminal type and 16 as basal type. The 5-year CSS and RFS were 76.2% and 64.2%, respectively. Among patients who received platinum-based neoadjuvant chemotherapy, those with the luminal subtype showed significantly better RFS than those with the basal subtype (P\u00a0=\u00a00.016, HR 5.27, 95%CI 1.15\u201324.1). However, no significant difference in CSS was observed between the luminal and basal subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Molecular subtypes can be inferred using common immunohistochemical markers, providing a practical approach for personalized treatment strategies. Further prospective studies are needed to validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf167","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:20:33Z","timestamp":1762651233000},"page":"221-225","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the utility of molecular subtype classification by immunohistochemistry in bladder cancer undergoing radical cystectomy: a retrospective cohort study"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5079-2171","authenticated-orcid":false,"given":"Yoshinori","family":"Ikehata","sequence":"first","affiliation":[{"name":"Department of Urology, University of Toyama , 2630 Sugitani, Toyama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotaka","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Toyama , 2630 Sugitani, Toyama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Toyama , 2630 Sugitani, Toyama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Toyama , 2630 Sugitani, Toyama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"2026021308522144600_ref1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00345-024-04949-8","article-title":"Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates","volume":"42","author":"Weber","year":"2024","journal-title":"World J Urol"},{"key":"2026021308522144600_ref2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Recurrence and progression of disease in non-muscle invasive bladder cancer: from epidemiology to treatment strategy","volume":"56","author":"Van Rhijn","year":"2009","journal-title":"Eur Urol"},{"key":"2026021308522144600_ref3","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.urolonc.2014.07.002","article-title":"Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice","volume":"32","author":"Van Rhijn","year":"2014","journal-title":"Urol Oncol"},{"key":"2026021308522144600_ref4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"2026021308522144600_ref5","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"2026021308522144600_ref6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"2026021308522144600_ref7","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"key":"2026021308522144600_ref8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"The Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"2026021308522144600_ref9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histology","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"2026021308522144600_ref10","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-19-4162","article-title":"Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from CheckMate 275","volume":"26","author":"Galsky","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026021308522144600_ref11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","article-title":"Different response to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes","volume":"81","author":"Sj\u00f6dahl","year":"2022","journal-title":"Eur Urol"},{"key":"2026021308522144600_ref12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-18640-0","article-title":"Molecular correlates of cisplatin-based chemotherapy response in muscle inva- sive bladder cancer by integrated multi-omics analysis","volume":"11","author":"Taber","year":"2020","journal-title":"Nat Commun"},{"key":"2026021308522144600_ref13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2020.02.028","article-title":"Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"2026021308522144600_ref14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2019.02.017","article-title":"The cancer genome atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability","volume":"75","author":"Kim","year":"2019","journal-title":"Eur Urol"},{"key":"2026021308522144600_ref15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification","volume":"242","author":"Sj\u00f6dahl","year":"2017","journal-title":"J Pathol"},{"key":"2026021308522144600_ref16","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41598-018-22126-x","article-title":"A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort","volume":"8","author":"Marzouka","year":"2018","journal-title":"Sci Rep"},{"key":"2026021308522144600_ref17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/path.6062","article-title":"The Lund taxonomy for bladder cancer classification \u2013 from gene expression clustering to cancer cell molecular phenotypes, and back again","volume":"259","author":"H\u00f6glund","year":"2023","journal-title":"J Pathol"},{"key":"2026021308522144600_ref18","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/path.5318","article-title":"Molecular pathology of the luminal class of urothelial tumors","volume":"249","author":"Bernardo","year":"2019","journal-title":"J Pathol"},{"key":"2026021308522144600_ref19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2022.01.006","article-title":"Molecular pathology of the non-luminal Ba\/Sq-like and Sc\/NE-like classes of urothelial tumours: an integrated immunohistochemical analysis","volume":"122","author":"Bernardo","year":"2022","journal-title":"Hum Pathol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/2\/221\/65224980\/hyaf167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/2\/221\/65224980\/hyaf167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:52:32Z","timestamp":1770990752000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/2\/221\/8315082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,5]]},"published-print":{"date-parts":[[2026,2,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf167","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,11,5]]}}}